



**CAUSE**



**AFFECT**



**EFFECT**

### PBA:

- Is associated with neurologic diseases such as MS, ALS, Parkinson's disease, dementias including Alzheimer's disease, and neurologic injuries such as stroke and TBI<sup>1,2</sup>
- It is hypothesized that these neurologic diseases and injuries impact the excitatory action of glutamate, leading to excessive glutamatergic signaling and increased electrical activity in neurons<sup>3-5</sup>

### PBA:

- Is a distinct neurologic disorder of affect characterized by involuntary episodes of motor expression of emotion, such as laughing, crying, or related facial features<sup>1</sup>
- PBA is surprisingly prevalent, affecting millions of patients and caregivers in the United States alone<sup>1,6-12</sup>
- The disorder is also commonly known as emotional lability, pathologic laughing and crying, and emotional incontinence<sup>1</sup>

### PBA:

- Can significantly impact patients and caregivers.<sup>6</sup> The symptoms of PBA can be severe, with persistent and unremitting episodes.<sup>13</sup> Involuntary crying or laughing may lead to embarrassment, anxiety, and depression, and result in social isolation<sup>6,13-16</sup>
- Addressing PBA can help improve the lives of patients and their families and caregivers,<sup>6</sup> thereby reducing its physical, emotional, and social impact

## Pseudobulbar Affect | PBA

For more information, please visit [www.PBAinfo.org](http://www.PBAinfo.org)

**References:** 1. Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. *Semin Clin Neuropsychiatry*. 2000;5:290-306. 2. Kaschka WP, Meyer A, Schier KR, et al. Treatment of pathological crying with citalopram. *Pharmacopsychiatry*. 2001;34:254-258. 3. Greenamyre JT. The role of glutamate in neurotransmission and in neurologic disease. *Arch Neurol*. 1986;43:1058-1063. 4. Bittigau P, Ikonomidou C. Glutamate in neurologic diseases. *J Child Neurol*. 1997;12:471-485. 5. Mattson MP. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. *Neuromolecular Med*. 2003;3:65-94. 6. Moore SR, Gresham LS, Bromberg MB, et al. A self report measure of affective lability. *J Neurol Neurosurg Psychiatry*. 1997;63:89-93. 7. Caroscio JT, Mulvihill MN, Sterling R, et al. Amyotrophic lateral sclerosis: its natural history. *Neural Clin*. 1987;5:1-8. 8. Gubbay SS, Kahana E, Zilber N, et al. Amyotrophic lateral sclerosis: a study of its presentation and prognosis. *J Neurol*. 1985;232:295-300. 9. Zeilig G, Drubach DA, Katz-Zeilig M, et al. Pathological laughter and crying in patients with closed traumatic brain injury. *Brain Inj*. 1996;10:591-597. 10. Tang WK, Chan SSM, Chiu HFK, et al. Emotional incontinence in Chinese stroke patients: diagnosis, frequency, and clinical and radiological correlates. *J Neurol*. 2004;251:865-869. 11. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. *Arch Neurol*. 1990;47:98-104. 12. Kim JS, Choi S, Kwon SU, et al. Inability to control anger or aggression after stroke. *Neurology*. 2002;58:1106-1108. 13. Dark FL, McGrath JJ, Ron MA. Pathological laughing and crying. *Aust N Z J Psychiatry*. 1996;30:472-479. 14. Shaibani AT, Sabbagh MN, Doody R. Laughter and crying in neurologic disorders. *Neuropsychiatry Neuropsychol Behav Neurol*. 1994;7:243-250. 15. Black DW. Pathological laughter. A review of the literature. *J Nerv Ment Dis*. 1982;170:67-71. 16. Green RL. Regulation of affect. *Semin Clin Neuropsychiatry*. 1998;3:195-200.